✦ LIBER ✦

Successful management of predicted severe ovarian hyperstimulation syndrome with gonadotropin-releasing hormone agonist

✍ Scribed by Tsung-Chieh Jackson Wu; Timothy J. Gelety; Ming H. Jih; Nicole Fournet; Richard Buyalos

Publisher: Springer US
Year: 1992
Tongue: English
Weight: 255 KB
Volume: 9
Category: Article
ISSN: 1573-7330
DOI: 10.1007/bf01203829

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A controlled ovarian hyperstimulation re

A controlled ovarian hyperstimulation regimen involving intermittent gonadotropin administration with a “short” protocol of gonadotropin releasing hormone agonist for in vitro fertilization

✍ Nobuhiko Suganuma; Shin-Ichiro Tsukahara; Takeshi Kitagawa; Madoka Furuhashi; Yo 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 553 KB

The advantages of a gonadotropin releasi

The advantages of a gonadotropin releasing hormone agonist (leuprolide acetate) in conjunction with gonadotropins for controlled ovarian hyperstimulation in IVF and GIFT cycles

✍ J. F. Kerin 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 496 KB

Successful outcome of severe ovarian hyp

Successful outcome of severe ovarian hyperstimulation syndrome (OHSS) with 27 liters of ascitic fluid removed by paracentesis

✍ D. Grochowski; E. Sola; M. Kulikowski; W. Kuczyński; S. Wolczyński; M. Szamatowi 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 375 KB

Gonadotropin-releasing hormone agonist a

Gonadotropin-releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis

✍ F. Parborell; L. Dain; M. Tesone 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

## Abstract Apoptosis is the biological process by which follicular cells are eliminated in atretic follicles. The aim of the present study was to examine the in vitro effect of a GnRH‐a (leuprolide acetate, LA) and its interactions with FSH, dibutyryl cAMP, and growth factors (IGF‐I, EGF, and FGF)

Use of a gonadotropin-releasing hormone

Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus

✍ Emily C. Somers; Wendy Marder; Gregory M. Christman; Vladimir Ognenovski; W. Jos 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## Objective Cyclophosphamide (CYC) therapy for systemic lupus erythematosus (SLE), a disease predominantly affecting women of childbearing age, causes an unacceptably high incidence of irreversible premature ovarian failure (POF). This study was performed to evaluate the effectiveness

Comparison of ovarian stimulation regime

Comparison of ovarian stimulation regimens for in vitro fertilization (IVF) with and without a gonadotropin-releasing hormone (GnRH) agonist: Results of a randomized study

✍ A. Berg Van De-Helder; F. M. Helmerhorst; A. Blankhart; R. Brand; C. Waegemaeker 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 445 KB